Showing 1781-1790 of 3038 results for "".
- Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470https://modernod.com/news/nicox-presents-phase-2-results-on-ncx-4251-and-new-nonclinical-evidence-of-improved-hemodynamic-and-retinal-cell-physiology-on-ncx-470/2480822/Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scien
- Registration Now Open for Neuro-Optometric Rehabilitation Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-annual-conference/2480810/Registration is now open for the Neuro-Optometric Rehabilitatio
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational NOV03 at ASCRShttps://modernod.com/news/bausch-lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-nov03-at-ascrs/2480800/Bausch + Lomb and Novaliq announced that data from the first pivotal phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibom
- Orasis Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-positive-phase-3-topline-results-of-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2480784/Orasis Pharmaceuticals announced that the phase 3 NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of CSF-1, its novel eye drop candidate, met their primary and key secondary endpoints. Additional details of these trials will be presented at future medical meet
- Nova Eye Medical Launches Next Generation Canaloplasty Device for Glaucoma, iTrack Advancehttps://modernod.com/news/nova-eye-medical-launches-next-generation-canaloplasty-device-for-glaucoma-itrack-advance/2480774/Nova Eye Medical announced the launch of its next generation canaloplasty device, iTrack Advance, in select markets in Europe and the Asia Pacific. The iTrack Advance features the proprietary illuminated fiber optic tip of the original iTrack device, which all
- Novartis Receives European Commission Approval of Beovu for Diabetic Macular Edema (DME)https://modernod.com/news/novartis-announces-european-commission-approval-of-beovu-for-diabetic-macular-edema-dme/2480740/Novartis announced that the European Commission (EC) has approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Today’s approval in DME represents the second indication for Beovu granted by the EC, which was first approved for the
- Nova Eye President Appointed to American Glaucoma Society (AGS) Foundation Advisory Boardhttps://modernod.com/news/nova-eye-president-appointed-to-american-glaucoma-society-ags-foundation-advisory-board/2480735/Nova Eye Medical has announced that Joe Bankovich, President of Nova Eye, has been appointed as an industry representative to the American Glaucoma Society Foundation Advisory Board. Established in 2011 and comprising over 1500 members, the American Glaucoma Society Foundation runs
- Retina Consultants of America Expands Washington State Footprint Through Partnership with Retina Center Northwesthttps://modernod.com/news/retina-consultants-of-america-expands-washington-state-footprint-through-partnership-with-retina-center-northwest/2480726/Retina Consultants of America (RCA), a physician management services organization, has added Retina Center Northwest (RCNW) in Washington state,. Terms of the deal were not disclosed. With the addition of RCNW, RCA adds to its presence in the Pacific Northwest, and
- New Multi-Language Options Now Available on Reichert.comhttps://modernod.com/news/new-multi-language-options-now-available-on-reichertcom/2480719/Reichert Technologies, a business unit of Ametek, has announced that Reichert.com is now available in five new language options: Chinese, French, German, Italian, and Spanish. Putting customers first will always be Reichert’s main focus. This new capability will help make the information on
- Nominations Now Being Accepted for NORA Awardshttps://modernod.com/news/nominations-now-being-accepted-for-nora-awards/2480704/Nominations are now being accepted by the Neuro-Optometric Rehabilitation Association, International (NORA) for the following awards, which acknowledge individuals and organizations for important contributions to the area of neuro-optometric rehabilitation. The Advancement